UNSPSC 51272113: Meprylcaine hydrochloride

This classification denotes an anesthetic agent with the molecular structure C14H21NO2.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, VR843X5GXG chemically known as 1-propanol-2-methyl-2-(propylamino)-, benzoate (ester), hydrochloride, but more commonly known as meprylcaine hydrochloride, which bears US NIH Compound Identifier 101925. European Medicines Agency schedules Meprylcaine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03160MIG.

Most nations, for tariff and trade purposes, schedule meprylcaine hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, MEPRYLCAINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Meprylcaine hydrochloride bears US NLM identifiers UMLS ID C2347107 and NCI Concept Code C72819. SMILES: CCCNC(C)(C)COC(=O)C1CCCCC1.CL.

UNSPSC 51272113 Meprylcaine hydrochloride is a Commodity code that in recent state and local procurement activity encompasses a much broader pharmaceutical and medical-supply acquisition landscape than the specific chemical name suggests. State and local governments are actually buying naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products through cooperative arrangements, and exploring direct-to-manufacturer prescription programs — reflecting public-health emergency response, routine pharmaceutical inventory management, and cost-containment strategy across health departments, county health systems, and state pharmacy benefit programs. The issuing bodies span county health departments (Seminole County, Florida), state pharmacy agencies (Texas Health and Human Services Commission), and regional purchasing cooperatives (Minnesota Multistate Cooperative Purchasing Alliance serving multiple states including Oregon and Minnesota).

Recent opportunities include Seminole County's IFB60459723LAS, posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building (response due July 26, 2023); the Texas HHS Commission's RFI No. HHS0017013, posted April 3, 2026, exploring vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements; and the Minnesota Department of Administration's MMCAP RFP S1070000015802, posted January 20, 2026, establishing multiple contracts for generic pharmaceuticals and OTC products distributed to state and local government facilities across participating jurisdictions (proposals due March 26, 2026). Activity concentrates in Florida, Texas, and the Upper Midwest, with MMCAP serving a multi-state cooperative base. The code shows active procurement spanning emergency medical supplies, routine generic pharmaceutical distribution, and exploratory initiatives around direct pharmaceutical sourcing — signaling ongoing demand from health departments and pharmacy benefit administrators across jurisdictional tiers.